Subject:
- Active Substance: Olipudase alfa
- Name: Xenpozyme®
- Therapeutic area: Acid sphingomyelinase deficiency (ASMD)
- Pharmaceutical company: Sanofi-Aventis Deutschland GmbH
Time table:
- Start: 01.10.2022
- Publication of assessment: 02.01.2023
- End of public hearing: 23.01.2023
- Final decision by G-BA: middle of March 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation